The US Recombinant Proteins Market was valued at $312.5 Million in 2023 and projected to reach to $473.3 Million by 2028, representing a compound annual growth rate of 8.7%. The US recombinant proteins market is poised for sustained growth through 2028, driven by escalating demand for biologic therapeutics and continued innovation in protein engineering technologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US recombinant proteins market reached $312.5 million in 2023 and is forecast to grow to $473.3 million by 2028, representing a robust 8.7% CAGR that outpaces the global average of 7.2%.
The US maintains its position as a global leader in recombinant protein development, driven by significant R&D investments from major pharmaceutical companies and biotechnology firms concentrated in regions like California, Massachusetts, and North Carolina.
Increasing clinical adoption of recombinant therapeutics for oncology, immunology, and rare diseases is expanding the addressable market, supported by favorable FDA approval pathways and reimbursement policies.
Strong US healthcare spending, advanced manufacturing capabilities, and robust regulatory frameworks create an optimal environment for recombinant protein commercialization and market expansion.
| Report Metric | Details |
|---|---|
| Base Year | 2023 |
| Fastest Growing Segment | INTERFERONS (IFNS) (Type) |
| Forecast Period | 2023-2028 |
| Growth Rate | CAGR of 7.2% from 2023 to 2028 |
| Largest Segment | PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User) |
| Market Size Base Year (Billions) | ~USD 2.26 (2023) |
| Revenue Forecast (Billions) | ~USD 3.2 (2028) |
| Segments Covered | Product, Type, Application, Host Cell, End User |
5 segment dimensions are covered across the global market.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC RESEARCH INSTITUTES | 192.3 | 198.6 | 211.1 | 226.2 | 243.4 | 262.9 | 285.1 | 309.5 | 8 |
| BIOTECHNOLOGY COMPANIES | 134.9 | 139.2 | 147.8 | 158.1 | 169.9 | 183.2 | 198.4 | 215.2 | 7.8 |
| CONTRACT RESEARCH ORGANIZATIONS | 70.8 | 72.9 | 77.2 | 82.4 | 88.3 | 95 | 102.6 | 110.9 | 7.5 |
| OTHER END USERS | 48.2 | 49.1 | 51.5 | 54.4 | 57.8 | 61.5 | 65.8 | 70.5 | 6.5 |
| PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES | 376.6 | 389.4 | 414.7 | 445 | 479.5 | 518.6 | 563.3 | 612.5 | 8.1 |
| TOTAL | 822.76 | 849.11 | 902.2 | 966.03 | 1038.83 | 1121.17 | 1215.29 | 1318.63 | 7.9 |
The US recombinant proteins market was valued at $312.5 million in 2023 and is expected to reach $473.3 million by 2028.
The US recombinant proteins market is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2028.
Key drivers include rising chronic disease prevalence, expanding biosimilar pipelines, strong biopharmaceutical R&D investment, FDA regulatory support, and growing demand for personalized medicine in the US.
The US recombinant proteins market is experiencing strong growth in oncology, immunology, and rare disease therapeutics, supported by advanced protein engineering innovations.
The US recombinant proteins market grows at 8.7% CAGR, outpacing the global market's 7.2% CAGR, reflecting the US's leadership in biopharmaceutical innovation and healthcare infrastructure.
This study involved four major activities in estimating the current size of the recombinant proteins market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the recombinant proteins market. The secondary sources used for this study include The Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), American Medical Association (AMA), Recombinant Antibody Network (RAN) National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Department of Agriculture (USDA), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), Institute for Molecular Medicine, Annual Reports, SEC Filings, Press Releases, Company Websites, Investor Presentations, Magazines, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global recombinant proteins market, which was validated through primary research.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
The global size of the recombinant proteins market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report

After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report